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The IL-1/IL-1R axis induces greater ﬁbroblast-derived
chemokine release in human papillomavirus-negative compared
to positive oropharyngeal cancer
Sarmad Al-Sahaf1, Keith D. Hunter1, Robert Bolt1, Penelope D. Ottewell2 and Craig Murdoch 1
1School of Clinical Dentistry, Claremont Crescent, University of Shefﬁeld, United Kingdom
2Department of Oncology & Metabolism, Medical School, Beech Hill Road, University of Shefﬁeld, United Kingdom
Human papillomavirus (HPV) is now recognised as a major aetiological agent in the pathogenesis of oropharyngeal
carcinoma (OPC). HPV-positive tumours are associated with better outcomes compared to HPV-negative tumours, possibly
due to differences in their aetiology and/or the tumour microenvironment. Increased numbers of tumour-associated
leukocytes have been observed in many cancers including OPC, with variable inﬂuence on prognosis depending on the
leukocyte subpopulation investigated. Whether HPV status inﬂuences leukocyte recruitment to OPC remains unknown.
This in-vitro study examined differences in the chemoattractant capacity of HPV-positive and HPV-negative OPC cell lines.
Gene and protein expression analysis demonstrated that whilst both monocultures of HPV-positive and HPV-negative cell
lines, along with normal tonsillar ﬁbroblasts (NTF), expressed low chemokine levels, NTF cultured with conditioned
medium from HPV-negative OPC cells expressed signiﬁcantly higher levels of all chemokines tested compared to NTF
incubated with the medium from HPV-positive OPC cell lines. HPV-negative OPC lines expressed IL-1β mRNA whereas HPV-
positive cells did not, and NTF constitutively expressed IL-1R1. Pre-treatment with the IL-R antagonist, anakinra or siRNA
to IL-1R1 signiﬁcantly reduced chemokine secretion from NTF stimulated with conditioned medium from HPV-negative
tumour cells or recombinant IL-1β (p < 0.05). These data suggest that secretion of chemokines is driven by the interaction
between HPV-negative OPC cells and stromal ﬁbroblasts through an IL-1/IL-1R-mediated mechanism that is less prominent
within the HPV-positive tumour microenvironment. These observations may explain differences in leukocyte sub-
populations recruited to HPV-positive versus negative OPC and indicate that HPV status is a key determinant in controlling
the inﬂammatory tumour microenvironment.
Introduction
Head and neck cancers (HNC) are the sixth most common
cancer globally and ninth most common malignancy in males
in the United States.1 These cancers are distributed through-
out the head and neck region, although much recent attention
has been paid to oropharyngeal carcinoma (OPC) due a
disproportionate increase in incidence over the past
10 years.2–4 The aetiology of OPC appears to be multi-
factorial and includes not only tobacco use and alcohol con-
sumption, but also human papillomavirus (HPV) infection,4,5
which now accounts for up to 65% of all OPC cases in the
United States6 and 50% in the United Kingdom.4
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Several studies have consistently demonstrated that indi-
viduals with HPV-positive OPC display better overall survival
compared to their HPV-negative, stage-matched
counterparts.7–9 HPV-positive tumours also display an
improved response to surgery, chemotherapy and radiother-
apy when compared to HPV-negative tumours.10,11 The rea-
sons for these differences remain largely unknown, although it
is generally accepted that the favourable prognosis of HPV-
positive OPC is related to the progressive genetic aberrations
acquired in HPV-negative cancers, including key cell cycle
regulators such as TP53 and RB1, whereas HPV-positive
tumours arise from the effects of viral oncoproteins E6 and
E7, which allow tumour cells to retain a wild-type TP53 and
RB1 status.12 Given the complex cellular interactions that
drive tumourigenesis; it is likely that disruption of other path-
ways are also important in promoting the development of
HPV-positive and -negative OPC.
The tumour microenvironment is instrumental in the pro-
gression of many cancers, particularly with respect to inﬂamma-
tion.13,14 In HPV-negative HNC, the presence of high numbers
of tumour-associated macrophages and neutrophils has been
associated with poor prognosis.15–17 In addition, HPV-negative
OPC has been shown to recruit immunosuppressive, regulatory
T-cells that may suppress any cytotoxic anti-cancer responses.18
Recent evidence suggests that HPV-positive tumours preferen-
tially attract CD8 T-cells, which, if present in high numbers, are
predictive of an improved outcome.19 Together these ﬁndings
suggest that the variation in leukocyte populations recruited to
HPV-positive versus HPV-negative tumours may have important
connotations for outcome and prognosis.20
Tumour-inﬁltrating leukocyte recruitment is mainly driven
by a large family of chemotactic cytokines (chemokines) that
are often up-regulated in cancer.21,22 These molecules direct the
movement of speciﬁc leukocyte subpopulations from the circu-
lation into the tumour milieu, with the nature of the inﬁltrating
leukocyte population, and therefore inﬂammatory burden,
being dependent on the composition of chemokines released.
Although OPC cell lines are able to secrete a number of chemo-
kines, there is increasing evidence that it is the crosstalk
between tumour cells and stromal ﬁbroblasts that is more
important for cancer progression.14 We have recently demon-
strated that HPV-negative cancer cells drive the secretion
of hepatocyte growth factor from oral ﬁbroblasts which, in
turn, inﬂuences tumour cell invasion; a mechanism that is
reduced in response to HPV-positive cells.23 It is therefore
plausible that the chemotactic cues driven by the tumour
microenvironment in HPV-positive OPC is different from
those in HPV-negative OPC and this may account for differ-
ences observed in tumour-associated leukocyte sub-populations.
However, to date there is little data on how tumour cell HPV
status may impact on chemokine expression in OPC. Therefore,
our study evaluated the expression of chemokines within an
in vitro model of HVP-positive and HPV-negative tumour/stro-
mal cell interactions to determine if HPV status has an inﬂu-
ence on the molecular drivers of leukocyte recruitment in OPC.
Materials and Methods
Cell culture
OPC cells UPCI-SCC89, UPCI-SCC72 (HPV-negative) and
UPCI-SCC90, UD-SCC2 (HPV-positive) were received through
material transfer agreement with Professor Susanne Gollin,
University of Pittsburgh. Hypopharyngeal carcinoma cell lines
used included FaDu (HPV-negative) and UPCI-SCC152 (HPV-
positive). Cell lines were authenticated by DNA short tandem
repeat analysis by the Genomics Core Facility at the University
of Shefﬁeld and HPV status conﬁrmed by the HPV Cytology
Screening Unit (Shefﬁeld Teaching Hospital NHS Foundation
Trust, UK). Normal tonsillar ﬁbroblasts (NTF) were isolated
from patients during routine tonsillectomies undertaken at the
Royal Hallamshire Hospital, Shefﬁeld Teaching Hospitals NHS
Foundation Trust with written, informed consent24 (ethical
approval 09/H1308/66). SCC89, SCC72, SCC90 cells and NTF
were cultured in Dulbecco’s Modiﬁed Eagle’s Medium and
SCC2, FaDu, SCC152 were grown in RPMI, all supplemented
with 10% v/v FCS, 2 mM L-glutamine, 100 IU penicillin and
100 μg/mL streptomycin in a humidiﬁed incubator with 5%
CO2, at 37
C. All materials were purchased from Sigma-
Aldrich, UK, unless otherwise stated. Most studies were per-
formed on NTF06 (female, age 29); however, additional studies
to conﬁrm consistency across NTF from different donors were
also performed (NTF01 (female, age 38), NTF319 (male, age
52) and NTF322 (female age 21)).
Generation of tumour cell conditioned medium
Tumour cell lines were seeded at 1 × 107 cells in 75cm2 ﬂasks
for 24 h in serum-containing medium, washed three times
with phosphate-buffered saline (PBS) then incubated with
6 mL serum-free medium for 24 h. Conditioned medium was
What’s new?
Rates of oropharyngeal cancer (OPC) are increasing, mainly due to human papillomavirus (HPV) infection. There is limited
understanding, however, about the affects of HPV status in OPC on tumor-stromal interactions, which inﬂuence tumor
development and progression. In this study, HPV-negative OPC cells were found to drive a robust chemokine secretion proﬁle
in stromal tonsillar ﬁbroblasts, whereas HPV-positive OPC cells exhibited relatively low chemokine expression. Increased
chemokine expression in stromal tonsillar ﬁbroblasts was mediated by the IL-1/IL-1R axis. The ﬁndings suggest that HPV
status plays a role in the recruitment of leukocyte sub-populations in the OPC tumor microenvironment, inﬂuencing
inﬂammatory activity.
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collected, centrifuged at 400g for 5 min to remove cell debris
and stored at −80 C. NTF were grown to 80% conﬂuence in
75cm2 ﬂasks, washed three times with PBS and then incubated
with either cancer cell line conditioned media or serum-free
medium for 24 h. Cancer cell+NTF or NTF alone conditioned
medium was then retrieved, centrifuged at 400g for 5 min and
stored at −80 C for later analysis. For IL-1R blocking experi-
ments, 6 × 105 NTF were incubated with 10 μg/mL anakinra
or placebo control (Amgen, Thousand Oaks, CA) for 2 h
before stimulation with conditioned medium from SCC89
OPC cells or medium containing 5 ng/mL recombinant IL-1β
as a positive control for 4 h. Levels of anakinra or placebo
were maintained throughout the experiment. A cytotoxicity
assay using the tetrazolium dye MTT was performed on ana-
kinra treated NTF as previously described.25
siRNA treatment of NTF
siRNA for IL-1R1 was performed according to the manufac-
turer’s instructions (FlexiTube, Qiagen). Brieﬂy, 3 × 105 NTF
seeded in 6-well plates were incubated with transfection complex
containing 300 nM siRNA (IL-1R1, oligonucleotide SI00017598)
and Hi-PerFect transfection reagent (both Qiagen) in serum-free
medium. The transfection complexes were added drop-wise to
cells and the tissue culture plates swirled to ensure equal distri-
bution of the transfection complex. Mock-transfected control
cells received transfection reagent alone. Cells were incubated
for 24 h at 37 C in 5% CO2 with serum-containing medium
before washing twice with PBS and addition of conditioned
medium from SCC89 cells. All medium was collected after 4 h
and analysed for chemokine content by ELISA.
Chemokine protein arrays and ELISA
Human chemokine arrays (C1 series, RayBiotech, USA) were
used to screen the medium from NTF cultured with conditioned
medium derived from HPV-positive or -negative OPC cell lines,
according to the manufacturer’s instructions. The relative expres-
sion levels of each chemokine were determined by densitometry
using Quantity One software (Biorad, USA). Commercially avail-
able ELISA kits for CXCL8, CCL2 (BD Biosciences) and CCL5
(R&D systems) were used to quantify protein levels according to
the manufacturer’s instructions.
RNA isolation, reverse transcription and quantitative
polymerase chain reaction (RT-qPCR)
Total RNA was isolated (BioLine, UK) and 500 ng reverse
transcribed (High-Capacity kit, Life Technologies, UK). qPCR
was performed using Taqman gene expression assays as fol-
lows: 0.5 μL cDNA was ampliﬁed using 5 μL TaqMan master-
mix, 3.5 μL nuclease-free water and 0.5 μL TaqMan gene
probes for CXCL1 (Hs00236937), CXCL5 (Hs01099660),
CXCL8 (Hs00174103), CCL2 (Hs00234140), CCL5
(Hs00982282), CCL7 (Hs00171147), IL-1α (Hs00174092) and
IL-1β (Hs00174097), 0.5 μL β-2-Microglobulin (Hs00984230)
was used as a reference control (Applied Biosystems).
Reactions were performed using thermal cycles of 50 C
(2 min) and 95 C (10 min) then 40 cycles of 15 s at 95 C
followed by 1 min at 60 C. The threshold cycle (Ct) was nor-
malised against the reference gene and then fold changes in
expression relative to the untreated NTF group calculated by
using the formula 2-ΔΔCt. For expression of IL-1α and IL-1β
by cancer cells, gene expression was normalised to the abun-
dance of the control gene transcript, β-2-microglobulin.
Immunoﬂuorescence staining of NTF
NTF were seeded on glass coverslips at 1 x104 cells in 24-well
plates and incubated overnight before being ﬁxed and permea-
bilised using 2% paraformaldehyde and 0.1% Triton-X-100 for
15 min. After blocking with bovine serum albumin for
30 min, cells were incubated with 5 μg/mL of either anti-IL-
1R1 (R&D Systems, clone 73,229), HLA class I (Sigma-
Aldrich, clone W6/32) or IgG control antibody (Abcam) at
4 C overnight. After washing with PBS, cells were incubated
with biotin-conjugated goat anti-mouse antibody (Abcam)
for 30 min then with phycoerythrin-conjugated streptavidin for
20 min at room temperature. after washing and mounting with
ProLong™ Diamond anti-fade containing 40,6-Diamidine-20-
phenylindole dihydrochloride (DAPI), cells were imaged using
a Zeiss880 AiryScan confocal microscope.
Statistics
All data are expressed as mean  SD of at least three indepen-
dent experiments unless otherwise stated. Statistical analysis was
performed using GraphPad Prism-v7.0 (GraphPad Software).
Group-wise comparisons were carried out using one-way inde-
pendent ANOVA with Tukey’s multiple comparisons test and
differences were considered signiﬁcant when p < 0.05.
Results
HPV-positive and HPV-negative-stimulated NTF display
differential chemokine expression
Chemokine protein array proﬁling showed that the condi-
tioned medium from the HPV-negative OPC cell lines SCC72
and SCC89 induced a robust and marked increase in overall
chemokine secretion by NTF06 compared to SCC2 and
SCC90 HPV-positive cells (Fig. 1). Semi-quantitative densito-
metric analysis showed abundant secretion of a broad
spectrum of CXC, CX3CL and CCL chemokines for HPV-
negative-stimulated NTF06, with particularly large increases
for neutrophil-speciﬁc (CXCL1, −5, −6, −8), monocyte-
speciﬁc (CCL7, −8) and T-lymphocyte (CCL3, −4, −5) che-
mokines. Although the protein array data gives an idea as to
the overall chemokine burden induced by HPV-positive/
negative tumour cell/stromal interactions, it is neither quanti-
tative nor reveals the cell origin of chemokine production.
Therefore, we used ELISA for a subset of leukocyte chemo-
kines - CXCL8 (neutrophils), CCL2 (monocytes) and CCL5
(T-cells) to determine whether cancer cells or NTF were
the main chemokine producers. Both HPV-negative and
Int. J. Cancer: 144, 334–344 (2019) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
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HPV-positive tumour cells and NTF06 alone express
extremely low levels of all chemokines tested (Fig. 2a,b,c).
Upon stimulation with conditioned medium from HPV-
positive cancer cells (SCC2, SCC90, SCC152) the amount of
chemokine in the conditioned medium was increased com-
pared to NTF06 alone, but was still relatively low. In contrast,
incubation of NTF06 with conditioned medium derived from
HPV-negative cancer cells (SCC72, SCC89 and FaDu) signiﬁ-
cantly increased the amount of CXCL8 (SCC89 p < 0.001 and
FaDu p < 0.01), CCL2 and CCL5 (at least p < 0.05 for all
HPV-negative cells) in the conditioned medium (Fig. 2d,e,f ).
For SCC89-treated NTF06, the increase in CXCL8 was
time-dependent, with the levels of this chemokine still increas-
ing after 24 h (Supporting Information Fig. S1). To show that
this stimulatory effect was not due to use of NTF06 alone,
NTF isolated from 3 other donors (NTF01, NTF319 and
NTF322) were stimulated with the conditioned medium from
HPV-positive SCC2 or HPV-negative SCC72 OPC cells. These
data show that, although some donor-to-donor variation was
observed, HPV-negative SCC72 conditioned medium consis-
tently induced signiﬁcantly (p < 0.01) greater chemokine
secretion from all the NTF tested than for HPV-positive
Figure 1. Normal tonsillar ﬁbroblasts (NTF), cultured with conditioned medium from HPV-negative OPC, secrete increased levels of
chemokines compared to HPV-positive OPC (a) Chemokine arrays were probed with conditioned medium from NTF06 incubated with SCC2
and SCC90 (HPV-positive) or SCC72 and SCC89 (HPV-negative) conditioned medium. (b) Bar chart shows densitometry analysis of arrays
where immunoblots were scanned and the density of the spots normalised to the intensity of the positive control spots to allow for
comparisons. Data shown are from one representative blot of two experimental repeats. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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SCC2 conditioned medium (Supporting Information Fig. S2).
The increased chemokine secretion by these NTF in response
to SCC72 conditioned medium was much reduced compared
to the levels observed for SCC89 conditioned medium (Figs. 1
and 6), showing that differences in NTF chemokine secretion
is HPV-negative cell line dependent.
HPV-negative, but not HPV-positive, conditioned medium
induces chemokine gene expression by NTF
Quantitative PCR was next performed to determine whether
induction of chemokine expression was extended to the
mRNA level. Expression of genes encoding the neutrophil-
speciﬁc chemoattractants, CXCL1, CXCL5 and CXCL8 were
Figure 2. HPV-negative conditioned medium stimulates markedly increased chemokine release from NTF than HPV-positive conditioned
medium. Chemokine release was quantiﬁed by ELISA in the conditioned medium of HPV-positive (SCC2, SCC90, SCC152) or HPV-negative
(SCC72, SCC89, FaDu) tumour cells cultured alone for (a) CXCL8 (b) CCL2 (c) CCL5. NTF06 were cultured with the conditioned medium
produced from either HPV-positive (SCC2, SCC90, SCC152) or HPV-negative (SCC72, SCC89, FaDu) tumour cells for 24 h and compared to NTF
cultured alone for (d) CXCL8, (e) CCL2 and (f ) CCL5. Data are mean  SD from at least 3 independent experiments performed in triplicate and
statistical analysis was achieved using a one-way independent ANOVA with Tukey’s post-hoc multiple comparison test. *at least p < 0.05
compared to NTF alone; ¶ p < 0.01 compared to SCC2, SCC90 and SCC152. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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all signiﬁcantly (p < 0.05) increased when NTF06 were cul-
tured with conditioned medium derived from HPV-negative
compared to NTF06 treated with HPV-positive-derived condi-
tioned medium or NTF06 cultured with medium alone
(Fig. 3a–c). Similar observations were found for genes
encoding the monocyte-speciﬁc chemokines CCL2 and CCL7
(Fig. 3d,f ). In addition, the gene encoding the T-cell chemo-
kine CCL5 was also signiﬁcantly increased by HPV-negative
conditioned medium but only for SCC89 and FaDu cells
(Fig. 3e). In all cases tested, the level of gene expression was
Figure 3. HPV-negative conditioned medium stimulates increased chemokine gene expression from NTF06 than HPV-positive conditioned medium.
NTF were cultured with the conditioned medium from either HPV-positive cells (SCC2, SCC90, SCC152) or HPV-negative (SCC72, SCC89, FaDu) for
24 h or NTF06 cultured alone and gene expression analysed by qPCR for (a) CXCL1, (b) CXCL5, (c) CXCL8, (d) CCL2, (e) CCL5 and (f) CCL7. Data are
presented as mean fold-change in gene expression  SD compared to NTF06 alone from 3 independent experiments performed in triplicate and
statistical analysis was achieved using a one-way independent ANOVA with Tukey’s post-hoc multiple comparison test. *at least p < 0.05 compared
to NTF alone; ¶ at least p < 0.05 compared to SCC2, SCC90 and SCC152; § p < 0.05 SCC72 compared to SSC2 and SCC152. [Color ﬁgure can be
viewed at wileyonlinelibrary.com]
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directly related to cell type in terms of the ability to induce
chemokine production by NTF06 with SCC89 < FaDu<SCC72.
Taken together, these data suggest that HPV-negative cancer
cells secrete factor(s) that induce chemokine gene, and in turn
protein, expression by NTF and that the factor(s) are largely
absent from HPV-positive conditioned medium.
IL-1β is expressed by HPV-negative but not HPV-positive
cancer cells
Chemokine gene expression is predominantly induced by pro-
inﬂammatory cytokines, usually by activation of the MAPK and
NFκB signalling pathways.26 This prompted us to examine the
expression of pro-inﬂammatory cytokines by HPV-positive and
HPV-negative OPC cells. Neither HPV-positive nor HPV-
negative cells expressed tumour necrosis factor-α (data not
shown). In contrast, IL-1α gene expression was detected in both
HPV-positive and HPV-negative cells, although gene expression
was signiﬁcantly elevated in the HPV-negative lines SCC89 and
FaDu (4- and three-fold, respectively) compared to all HPV-
positive cell lines (p < 0.01, Fig. 4a). Differential expression of
IL-1β was even more evident; with HPV-positive cells expres-
sing negligible levels, whilst HPV-negative cells all expressed
abundant IL-1β transcripts, with highly signiﬁcant increases
observed for SCC89 and FaDu (p < 0.01, Fig. 4b). We further
conducted a preliminary study using biopsy tissue sections
from HPV-positive and HPV-negative OPC to examine IL-1β
expression in vivo by immunohistochemical analysis. We found
that IL-1β was minimally expressed in normal tonsillar epithe-
lium. In contrast, the presence of IL-1β was generally observed
in most HPV-negative OPC tumour cells, whereas expression
was not observed in most HPV-negative OPC tumour cells.
However, staining was variable amongst sections and the pres-
ence of IL-1β was observed in tumour sections from certain
HPV-positive biopsies (Supporting Information Fig. S3).
Both IL-1α and IL-1β potentiate their pro-inﬂammatory
actions by binding to IL-1R expressed by target cells. Immuno-
ﬂuorescence staining of NTF06 cells using a speciﬁc anti-human
IL-1R1 antibody followed by confocal microscopy analysis
showed punctate expression of IL-1R1 in NTF, providing evi-
dence of both cell surface and intracellular receptor expression
(Fig. 4c). A similar staining pattern was observed for NTF iso-
lated from different donors (Supporting Information Fig. S4).
IL-1/IL-1R axis mediates NTF chemokine expression by HPV-
negative cancer cells
To determine whether the IL-1 expressed by HPV-negative
cells was responsible for inducing chemokine release via
IL-1R, NTF06 were incubated with conditioned medium
derived from SCC89 cells in the presence or absence of the
highly speciﬁc IL-1R1 antagonist anakinra, and levels of
Figure 4. HPV-negative tumour cells express abundant IL-1α and IL-1 β gene transcripts. Gene expression of (a) IL-1α and (b) IL-1β by HPV-positive
(SCC2, SCC90, SCC152) or HPV-negative (SCC72, SCC89, FaDu) tumour cells was quantiﬁed by qPCR. Expression of IL-1α and IL-1β was normalised
to the internal reference control gene, β-2-microglobulin to provide measures of relative expression for each cell line. Data presented from
3 independent experiments performed in triplicate and statistical analysis was achieved using a one-way independent ANOVA with Tukey’s post-
hoc multiple comparison test. *at least p < 0.05 compared to SCC2; ¶ at least p < 0.05 compared to SCC2, SCC90 and SCC152. (b) Expression of IL-
1R1 on NTF06 by immunoﬂuorescence staining. Cells were ﬁxed, permeabilised and stained with a monoclonal antibody for IL-1R1, HLA class I
(positive control) or IgG (negative control) and visualised by confocal microscopy. NTF displayed cell surface and intracellular IL-1R1 expression.
Data show images from one NTF but are representative of 3 independent experiments. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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CXCL8, CCL2 and CCL5 secreted quantiﬁed by ELISA.
Medium from SCC89 cells was used in these experiments
because these cells were identiﬁed as expressing most abun-
dant IL-1 as well as generating a robust chemokine release
proﬁle by NTF. An MTT cytotoxicity assay was initially used
to conﬁrm that neither anakinra nor the placebo control were
toxic to NTF in concentrations up to 100 μg/mL (Supporting
Information Fig. S5). As with previous data, both NTF and
SCC89 when incubated alone expressed minimal CXCL8 and
CCL2, whereas NTF06 incubated in SCC89 conditioned
medium signiﬁcantly induced the secretion of both chemo-
kines (Fig. 5b,c). Pre-incubation of NTF06 with anakinra sig-
niﬁcantly (p < 0.01) abrogated secretion of CXCL8 and CCL2,
reducing levels to that of unstimulated NTF06. Interestingly,
pre-incubation with the placebo signiﬁcantly (p < 0.01)
reduced levels of CXCL8 whilst increasing levels of CCL2
(p < 0.01) although in both instances the levels of these che-
mokines were still signiﬁcantly higher than that detected after
anakinra treatment (p < 0.01, Fig. 5a,b). The pattern of CCL5
expression differed to that of CXCL8 and CCL2. Overall,
levels of CCL5 were much lower than those observed for
CXCL8 or CCL2. CCL5 was detected in SCC89 medium
alone, although secretion signiﬁcantly increased when the
media was incubated with NTF06 (p < 0.05). Treatment with
anakinra signiﬁcantly (p < 0.01) reduced CCL5 levels,
although not back to baseline, whilst treatment with placebo
had no effect (Fig. 5c). To conﬁrm speciﬁcity, IL-1R1 gene
expression by NTF06 was reduced using gene speciﬁc siRNA
oligonucleotide probes (expression reduced by 88  3% when
analysed by qPCR). When incubated with SCC89 conditioned
medium, secretion of CXCL8 was signiﬁcantly reduced from
8.0 0.9 ng/mL in mock-transfected NTF06 to 3.6 0.9 ng/mL
(p < 0.01) in siRNA treated cells (Fig. 5d). To determine that
this phenomenon was not due to one individual NTF batch,
we repeated the anakinra blocking experiment with NTF
derived from 3 separate donors and tested for CXCL8 release
in response to SCC89 conditioned medium. Treatment of all
batches of NTF with SCC89 conditioned medium led to a sig-
niﬁcant increase in CXCL8 secretion (p < 0.001). In addition,
pre-incubation with anakinra resulted in a total abrogation of
CXCL8 chemokine secretion (p < 0.001) in response to condi-
tioned medium derived from SCC89 cancer cells for all NTF
tested that was not evident in the placebo control (Fig. 6).
Moreover, treatment of these NTF with recombinant IL-1β
also induced a prominent CXCL8 response that was likewise
completely inhibited by the IL-1R antagonist (Fig. 6).
Figure 5. NTF chemokine release by HPV-negative conditioned medium is driven by an IL-1/IL-1R1 axis. (a) NTF06 cells were incubated with anakinra
or placebo then stimulated with the conditioned medium from SCC89 tumour cells for 4 h and levels of chemokines (b) CXCL8, (c) CCL2 and (d) CCL5
quantiﬁed in the medium by ELISA and compared to levels of these chemokines from NTF06 incubated with the conditioned medium from SCC89
cells without treatment, or the conditioned medium from SCC89 or NTF cells cultured alone. In each case chemokine secretion was signiﬁcantly
decreased by pre-incubation with the IL-1R antagonist anakinra compared to placebo control. (d) NTF06 were treated with siRNA to ablate IL-1R1
expression and then stimulated with conditioned medium from SCC89 cells. siRNA-treated Cells exhibited a signiﬁcant decrease in CXCL8 secretion
compared to mock-transfected NTF06 cells. Data are mean SD from at least 3 independent experiments performed in triplicate. Statistical analysis
for a, b and c was achieved using a one-way independent ANOVA with Tukey’s post-hoc multiple comparison test. In panel D, statistical analysis was
a Mann–Whitney U test for 4 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Discussion
Despite the often late diagnosis of HPV-positive OPC and
lymph node involvement, prognosis is signiﬁcantly better than
that of its HPV-negative counterpart.27 It has been proposed
that this improved prognosis is related, in part, to differences
in the immune response of these tumours,28 which, by
extension, may be related to levels of tumour-inﬁltrating leu-
kocytes. However, data relating to the nature of leukocyte-
recruiting chemokines released from HPV-positive and HPV-
negative OPC is lacking. The tumour microenvironment
involves crosstalk between cancer and stromal cells13,29 and
this interaction appears to be crucial for many aspects of can-
cer progression.23,30 We therefore used a 2D in vitro model to
examine HPV-positive versus HPV-negative cancer-stromal
interactions, and how such interactions may inﬂuence micro-
environmental chemokine release.
Chemokine protein array data demonstrated that the condi-
tioned medium from HPV-negative OPC when incubated with
NTF contained increased amounts of chemokines encompassing
most chemokine family members. Several previous reports have
shown that OPC cells have the ability to express chemokines,31–33
indeed, our quantitative analysis showed that CXCL8, CCL2 and
CCL5 were all expressed by both HPV-negative, HPV-positive
and NTF but at very low levels. However, secretion of these che-
mokines along with others were substantially increased when all
NTF examined were stimulated with the conditioned medium
from HPV-negative, but not HPV-positive cells. Moreover, gene
expression analysis showed that HPV-negative conditioned
medium was able to activate the transcription of several chemo-
kine genes by NTF, whereas HPV-positive conditioned medium
did not. The chemokine response by NTF was cell line dependent
with some HPV-negative cells lines stimulating more chemokine
expression than others, suggesting some level of heterogeneity
between these cells that may be dependent upon their genetic
background. These data not only show differential activation of
chemokine genes in response to conditioned media depending on
tumour line HPV-status, but also point to a pro-inﬂammatory
cytokine as the molecular trigger.
The most studied and potent of inﬂammatory mediators
belong to the TNF and IL-1 families. We found transcripts for
IL-1α and IL-1β preferentially in HPV-negative cells. Indeed, IL-
1β was expressed exclusively in HPV-negative OPC. Constitutive
expression of IL-1β has been detected previously in keratino-
cytes34 where levels increase upon immune stimulation or malig-
nant transformation.35,36 Moreover, Wu et al. showed that
silencing IL-1β with lentivirus-delivered shRNA signiﬁcantly
inhibited oral squamous cell carcinoma cell growth both in vivo
Figure 6. IL-1/IL-1R1 axis increases chemokine secretion by NTF
isolated from different donors. (a) NTF01, (b) NTF319 and (c) NTF322
were pre-treated with anakinra or placebo then stimulated with the
conditioned medium from SCC89 tumour cells or 5 ng/mL IL-1β and
levels of CXCL8 in the conditioned medium quantiﬁed by ELISA and
compared to levels of this chemokine from NTF incubated with the
conditioned medium from SCC89 cells without treatment, or the
conditioned medium from SCC89 or NTF cells cultured alone. In each
case CXCL8 secretion was signiﬁcantly decreased when pre-incubated
with the IL-1R antagonist anakinra compared to placebo control. Data
are mean  SD from 3 independent experiments performed in
triplicate. Statistical analysis was achieved using a one-way
independent ANOVA with Tukey’s post-hoc multiple comparison test.
***p < 0.001. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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and in vitro, heavily implicating IL-1β as a key regulator of the
tumour microenvironment during HPV-negative oral cancer
development.36 Curiously, a complete lack of IL-1β expression has
been observed in HPV-positive cervical carcinoma cells lines,
implying HPV as a central driving force in IL-1β ablation. Niebler
et al., showed that infection of primary keratinocytes with HPV16
E6, but not E7, abrogated IL-1β processing and secretion in a
proteasome-dependent manner that was mediated by ubiquitin
ligase E6-AP and p53.35 The authors further suggest that continual
IL-1β ablation leads to complete loss of IL-1β gene altogether as
HPV-mediated malignancy develops.35 It is tempting to speculate
that a similar mechanism also exists in HPV-positive OPC cells
and this may explain the difference in IL-1β expression between
in vitro cultured HPV-positive and HPV-negative OPC cells
observed in our study. Indeed, in preliminary immunohistochemi-
cal studies on a small number of human HPV-negative and HPV-
positive OPC biopsies, we found, in general, that HPV-negative
tumour cells appeared to express more abundant levels of IL-1β
than HPV-positive tumour cells. However, we also observed IL-1β
expression by some HPV-positive tumour cells, suggesting that
loss of IL-1β in vivo is not absolute. It is plausible that expression
levels of IL-1β may differ signiﬁcantly by HPV status in vivo and
therefore a larger cohort study examining IL-1β levels in HPV-
negative/positive OPC is warranted.
Although our study is the ﬁrst to identify IL-1R1 expression on
tonsillar ﬁbroblasts, this receptor has been detected previously on
gingival ﬁbroblasts.37 We used anakinra, a highly speciﬁc IL-1R
antagonist that has been used clinically to treat auto-inﬂammatory
diseases,38,39 to block cancer cell derived IL-1 binding to the NTF
IL-1R, to show that CXCL8, CCL2 and CCL5 release is driven in
NTF by the IL-1/IL-1R axis, presumably via IL-1β secreted by
HPV-negative OPC. In support of these ﬁndings, siRNA ablation
of NTF IL-1R1 also signiﬁcantly reduced chemokine secretion in
response to HPV-negative SCC89 conditioned medium. Inhibition
of chemokine secretion using siRNA to IL-1R was not as effective
as inhibition with anakinra. This may be due to more efﬁcient
blockade of IL-1R by anakinra compared to siRNA treatment
where IL-1R was reduced by 88%, and so signalling may occur
through the IL-1R still expressed by si-RNA treated cells. In addi-
tion, we used siRNA speciﬁc for IL-1R1 and so IL-1β may exert its
actions on other IL-R family members expressed by NTF. Our
data provides evidence that OPC HPV status may radically inﬂu-
ence tumour biology by altering the inﬂammatory microenviron-
ment. Indeed, increased levels of IL-1β have been found in the cell
constituents of HPV-negative compared to HPV-positive OPC,
supporting the observations in our study.32
One of the major roles of chemokines in tumour biology is
to attract leukocytes to tumour tissue. Although no study has
reported data speciﬁc to HPV-positive/negative OPC, abundant
tumour-associated macrophages and neutrophils have been
found in HPV-negative tumours in animal models, and in
human HNC where they have been linked to poor progno-
sis.15,16,40,41 This may be due to the actions of tumour-derived
IL-1β on stromal ﬁbroblasts, as evidenced in our study. More-
over, once recruited, tumour-associated leukocytes, in particular
macrophages, may secrete additional IL-1β further potentiating
a feedback loop of chemokine release, leukocyte recruitment
and inﬂammation within the tumour microenvironment that
drives tumour progression.42 Although further studies are war-
ranted, it is interesting to speculate that IL-1/IL-1R inhibitors
may prevent accumulation of tumour-associated myeloid cells,
improving outcome. Although there are inherent problems with
IL-1R blockade, inhibition of IL-1β has shown promising
results in animal models of several cancers.43,44
Whilst chemokines driving myeloid cell inﬁltration appear to
promote tumour progression, there is evidence that recruitment
of certain T-cell populations is associated with improved progno-
sis. Indeed, in a prospective study, the presence of elevated levels
of tumour-inﬁltrating CD8+ T-cells correlated with a good prog-
nosis in HPV-positive compared to HPV-negative OPC.19,32,45,46
Interestingly, we found levels of CCL5 as well as other T-cell che-
mokines were elevated in HPV-negative compared to HPV-
positive OPC stromal interactions. It is possible that CD8 cells
may be recruited by chemokines or other factors not analysed in
our study. CD8-cell recruitment may be suppressed in HPV-
negative tumours even in the presence of elevated chemokines,
possibly by the elevated presence of myeloid-derived suppressor
cells or regulatory T-cells. Although representative OPC cell line
panels were chosen for use in our study, the reported data cannot
be readily generalised to clinical disease. 2D tumour/stromal inter-
actions in vitro are not representative of tumours in vivo due to
tumour hypoxia, nutrient exhaustion, and changes in vasculature
supply. The data presented in our study will therefore need con-
ﬁrmation through in vivo and human cancer tissue studies.
In summary, we have found for the ﬁrst time, that HPV-
negative OPC cells constitutively express IL-1 that stimulates
signiﬁcant chemokine release from tonsillar ﬁbroblasts via spe-
ciﬁc interaction with IL-1R, whereas this molecular mechanism
was less prominent in HPV-positive OPC cells. IL-1-driven
chemokine release may have a key role in the increased neutro-
phil and macrophage burden observed in HPV-negative can-
cers, which is often associated with poor prognosis.
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